B. Riley Securities Reiterates Buy on Exagen, Lowers Price Target to $8
Benzinga Newsdesk 9 months ago
NewsPrice TargetReiterationAnalyst Ratings
B. Riley Securities analyst Anderson Schock reiterates Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $18 to $8.
B. Riley Securities analyst Anderson Schock reiterates Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $18 to $8.